H-Immune

Pierre Fabre, H-Immune partner to develop cancer immunotherapies

Tuesday, March 21, 2017

Pierre Fabre, a privately held pharmaceutical company in France, and H-Immune, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.

[Read More]